U2Bio Co., Ltd.
U2Bio Co., Ltd. provides healthcare services in South Korea. The company also offers specimen testing services; digital healthcare services related to testing and health examinations; and bio-technology platforms. The company was founded in 2009 and is headquartered in Seoul, South Korea.
Market Cap & Net Worth: U2Bio Co., Ltd. (221800)
U2Bio Co., Ltd. (KQ:221800) has a market capitalization of $178.84 Million (₩261.86 Billion) as of March 18, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #18961 globally and #731 in its home market, demonstrating a 1.31% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying U2Bio Co., Ltd.'s stock price ₩23200.00 by its total outstanding shares 11287196 (11.29 Million).
U2Bio Co., Ltd. Market Cap History: 2023 to 2026
U2Bio Co., Ltd.'s market capitalization history from 2023 to 2026. Data shows growth from $40.70 Million to $178.84 Million (53.83% CAGR).
U2Bio Co., Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how U2Bio Co., Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
U2Bio Co., Ltd.'s market cap is 0.00 times its annual revenue
0.69x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $40.70 Million | $30.79 Billion | $645.90 Million | 0.00x | 0.06x |
| 2024 | $20.54 Million | $25.04 Billion | -$2.84 Billion | 0.00x | N/A |
Competitor Companies of 221800 by Market Capitalization
Companies near U2Bio Co., Ltd. in the global market cap rankings as of March 18, 2026.
Key companies related to U2Bio Co., Ltd. by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #90 globally with a market cap of $177.20 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #151 globally with a market cap of $122.79 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.38 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #511 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #90 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.20 Billion | $472.71 |
| #151 | Danaher Corporation | NYSE:DHR | $122.79 Billion | $195.21 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.38 Billion | $586.98 |
| #511 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
U2Bio Co., Ltd. Historical Marketcap From 2023 to 2026
Between 2023 and today, U2Bio Co., Ltd.'s market cap moved from $40.70 Million to $ 178.84 Million, with a yearly change of 53.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩178.84 Million | +491.84% |
| 2025 | ₩30.22 Million | +47.09% |
| 2024 | ₩20.54 Million | -49.53% |
| 2023 | ₩40.70 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of U2Bio Co., Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $178.84 Million USD |
| MoneyControl | $178.84 Million USD |
| MarketWatch | $178.84 Million USD |
| marketcap.company | $178.84 Million USD |
| Reuters | $178.84 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.